Search

Your search keyword '"LeBrun LA"' showing total 71 results

Search Constraints

Start Over You searched for: Author "LeBrun LA" Remove constraint Author: "LeBrun LA"
71 results on '"LeBrun LA"'

Search Results

1. US Primary Care Delivery After the Health Center Growth Initiative: Comparison of Health Centers, Hospital Outpatient Departments, and Physicians' Offices.

2. Access to primary and preventive care among foreign-born adults in Canada and the United States.

3. Characteristics of ambulatory care patients and services: a comparison of community health centers and physicians' offices.

7. Enhancing the measurement of health disparities for vulnerable populations.

8. Forecasting the dynamics of a complex microbial community using integrated meta-omics.

9. Alterations of oral microbiota and impact on the gut microbiome in type 1 diabetes mellitus revealed by integrated multi-omic analyses.

10. CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.

11. Roles of bacteriophages, plasmids and CRISPR immunity in microbial community dynamics revealed using time-series integrated meta-omics.

12. Integration of time-series meta-omics data reveals how microbial ecosystems respond to disturbance.

13. Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.

14. Expressed protein profile of a Tectomicrobium and other microbial symbionts in the marine sponge Aplysina aerophoba as evidenced by metaproteomics.

15. Sequential Isolation of DNA, RNA, Protein, and Metabolite Fractions from Murine Organs and Intestinal Contents for Integrated Omics of Host-Microbiota Interactions.

16. First draft genome sequence of a strain belonging to the Zoogloea genus and its gene expression in situ.

18. Integrated multi-omics of the human gut microbiome in a case study of familial type 1 diabetes.

19. Identification, Recovery, and Refinement of Hitherto Undescribed Population-Level Genomes from the Human Gastrointestinal Tract.

20. In situ phenotypic heterogeneity among single cells of the filamentous bacterium Candidatus Microthrix parvicella.

21. Comparative integrated omics: identification of key functionalities in microbial community-wide metabolic networks.

22. Community-integrated omics links dominance of a microbial generalist to fine-tuned resource usage.

23. Systematic design of 18S rRNA gene primers for determining eukaryotic diversity in microbial consortia.

24. Overweight/obesity and weight-related treatment among patients in U.S. federally supported health centers.

25. Development of the Chinese primary care assessment tool: data quality and measurement properties.

26. Racial/ethnic differences in clinical quality performance among health centers.

27. Clinical quality performance in U.S. health centers.

28. Primary care and public health activities in select US health centers: documenting successes, barriers, and lessons learned.

29. Effects of length of stay and language proficiency on health care experiences among immigrants in Canada and the United States.

30. Health, behavior, and health care disparities: disentangling the effects of income and race in the United States.

32. Cancer screening among racial/ethnic and insurance groups in the United States: a comparison of disparities in 2000 and 2008.

33. Nativity status and access to care in Canada and the U.S.: factoring in the roles of race/ethnicity and socioeconomic status.

34. Access to medical care, dental care, and prescription drugs: the roles of race/ethnicity, health insurance, and income.

35. Physician specialty and the quality of medical care experiences in the context of the Taiwan national health insurance system.

36. Assessing the impact of the Health Center Growth Initiative on health center patients.

38. The influence of English proficiency on access to care.

39. Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase.

40. 5,5'- and 6,6'-dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.

41. Cancer prevention behaviors in low-income urban whites: an understudied problem.

42. 5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.

43. Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents.

44. Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.

45. 4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase.

46. Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase.

47. Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.

48. Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.

49. Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.

50. ATLAS--a high-throughput affinity-based screening technology for soluble proteins: technology application using p38 MAP kinase.

Catalog

Books, media, physical & digital resources